secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001193125-22-277423
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma appoints Dr. Carol Gallagher to board, replacing Thilo Schroeder
---------------------------------------------------------------------------

- Thilo Schroeder resigned from board effective Nov 3, 2022; resignation not related to any disagreement.
- Carol Gallagher, Pharm.D., appointed as Class I director effective Nov 3, 2022.
- Gallagher has over 30 years biotech leadership and currently serves as venture partner at NEA.
- She joins PMV as the company notes recent clinical proof of concept for lead candidate PC14586.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/0001193125-22-277423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/d389567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-277423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer